About
Endovascular Engineering, Inc. (E2) is a medical device company based in Menlo Park, California. The company is dedicated to developing advanced technologies for clot removal, specifically targeting venous thromboembolism (VTE) and pulmonary embolism (PE). E2 is led by an experienced executive team and collaborates with clinical partners in interventional cardiology and radiology to enhance treatment outcomes for patients with blood clots. E2's flagship product is the Hēlo™ Thrombectomy System, a mechanical device designed to safely and effectively remove blood clots from the lungs and veins. The Hēlo™ system is currently undergoing clinical evaluation through the ENGULF Investigational Device Exemption (IDE) study at multiple leading U.S. medical centers. E2 primarily serves healthcare providers in interventional cardiology, interventional radiology, and vascular surgery, focusing on hospitals and medical centers that perform endovascular procedures. The company is committed to innovation and collaboration to improve the treatment landscape for VTE.
Technologies
Keywords
Company Information
- Employees37
- Founded2019
- Annual Revenue$4500000
- Total Funding$57000000
Location
3925 Bohannon Dr, Menlo Park, California, United States, 94025-1002
